Hofseth BioCare's (HBC) results for Q3 2013 will be reported on 11 November. Presentation of the Q3 results will take place at Carnegie's Office in Grundingen 2, Oslo on 11 November 2013 at 13:00. For attendance, please send an email to events@carnegie.no
HBC announced today increased order volumes from the U.S. The company has worked to obtain higher quality on our products in order to sell a larger share of volumes to sports- and pet nutrition. Because of the current high quality obtained in our products, HBC has stopped sales of salmon oil and soluble protein to animal feed. These products are now sold mainly to the human nutrition market. The implemented change in sales strategy entails a substantial increase in revenues in Q3 and Q4, and the company expects sales between 100 and 120 metric tons of finished products per month from now until the end of 2013.
For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Tel : +47 936 32 966
E-mail: joo@h-bc.no
Øystein Omvik, CFO of Hofseth BioCare ASA
Tel : +47 936 99 400
E-mail: oystein.omvik@h-bc.no
Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBCs objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.